Thank you Bourbon for your update from the ASM. As others have said, patience is warranted while the clinical trials proceed. It is encouraging and exciting to learn about this science as we watch it unfold before our eyes. Thank you to all of you who have been adding to our understanding of that science. Let us hope the trials continues to unfold favorably, so we can be telling our grandchildren about it in the future! Watching and waiting. ToeMind
I said back in 2015 that seizures could be a huge market for 2-73.
Having to run phase 3 trials will be expensive and lengthy. That may push the timeline out another year or two. But that’s a fact that every biotech has to face. Hopefully the trials can be expedited with the new tests AVXL and the other companies are developing.
Hopefully licensing for at least one of the 3 current indications in a phase 2/3 occurs before a phase 3 is needed. That way some upfront cash can help fund the trials.